Results 71 to 80 of about 2,896 (157)

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia

open access: yesOncology and Therapy
The approval of ibrutinib over a decade ago introduced Bruton tyrosine kinase (BTK) inhibition as a foundational, chemotherapy-free treatment approach for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Paolo Ghia   +3 more
doaj   +1 more source

Costs and consequences of cardiovascular toxicity due to Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia

open access: yesRevista Portuguesa de Cardiologia
Introduction and objectives: BTK inhibitors (BTKis) have revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL). However, a higher risk of cardiovascular toxicity is reported among CLL patients treated with BTKis. This study aims to
Débora Figueira   +7 more
doaj   +1 more source

Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia

open access: yesCase Reports in Medicine
Waldenström’s macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib.
Silvia Robuffo   +6 more
doaj   +1 more source

Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China

open access: yesHealth Economics Review
Objective To evaluate the cost-effectiveness of zanubrutinib compared to ibrutinib in the first-line treatment of chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) from the perspective of the Chinese healthcare system. Methods A three-
Ying Liu   +4 more
doaj   +1 more source

Zanubrutinib

open access: yesAmerican Journal of Health-System Pharmacy, 2020
openaire   +2 more sources

Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma. [PDF]

open access: yesBlood Adv
Martin-Moro F   +40 more
europepmc   +1 more source

Case Report: Zanubrutinib for refractory immune thrombotic thrombocytopenic purpura. [PDF]

open access: yesFront Immunol
De Angelis AD   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy